[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349484-105":59,"doc-detail-349484-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","discovery-of-smd-6346-a-potent-selective-and-orally-active-smarca2-degrader-for-targeting-smarca4-deficient-human-cancers","Discovery of SMD-6346 - A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers","","Selective targeting of SMARCA2 through targeted degradation is presented as a promising therapeutic approach for human cancers with deficient SMARCA4. The work reports discovery of potent, selective, and orally available SMARCA2 PROTAC degraders exemplified by SMD-6346. SMD-6346 shows DC50 = 3.3 nM and Dmax > 90% for SMARCA2 with only modest SMARCA4 activity (DC50 > 1000 nM, Dmax = 46%). It inhibits growth in SMARCA4-deficient models, has minimal effect in SMARCA2/4 wild-type cells, and reaches 61% oral bioavailability in mice.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/discovery-of-smd-6346-a-potent-selective-and-orally-active-smarca2-degrader-for-targeting-smarca4-deficient-human-cancers/349484/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/discovery-of-smd-6346-a-potent-selective-and-orally-active-smarca2-degrader-for-targeting-smarca4-deficient-human-cancers/349484.png","ImageObject",300,407,{"name":92,"@type":93},"Guten tag","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What therapeutic strategy does the article focus on for SMARCA4-deficient cancers?","Question",{"text":113,"@type":114},"It focuses on selectively targeting SMARCA2 via degradation, using SMARCA2 PROTAC degraders to exploit the dependency created by SMARCA4 deficiency.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What are the key potency and selectivity results for SMD-6346?",{"text":118,"@type":114},"SMD-6346 achieves DC50 = 3.3 nM and Dmax > 90% against SMARCA2, while showing only modest activity against SMARCA4 (DC50 > 1000 nM, Dmax = 46%).",{"name":120,"@type":111,"acceptedAnswer":121},"How does SMD-6346 perform in biological models regarding cell growth and in vivo exposure?",{"text":122,"@type":114},"It potently inhibits cell growth in SMARCA4-deficient cancer cell lines with minimal inhibition in SMARCA2/4 wild-type lines, and it shows an excellent pharmacokinetic profile with 61% oral bioavailability in mice.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},349484,1790558440,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","This article is licensed under CC-BY-NC-ND 4.0  \n[pubs.acs.org/jmc](pubs.acs.org/jmc)  Article   \nDiscovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers  \nLingying Leng,\\# Liyue Huang,\\# Wenbin Tu, Wei Jiang, Rohan Kalyan Rej, Srinivasa Rao Allu, Yu Wang, Mi Wang, Jelena Tǒsovíc, Meilin Wang, Bo Wen, Duxin Sun, and Shaomeng Wang*  \n Cite This: J. Med. Chem. 2026, 69, 15928−15944  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: Selective targeting SMARCA2 by degradation represents a promising new therapeutic strategy for human cancers harboring deficient SMARCA4. Herein we report the discovery of highly potent, selective and oral available SMARCA2 PROTAC degraders, as exemplified by SMD-6346. SMD- 6346 achieves DC50 = 3.3 nM and Dmax > 90% against SMARCA2 and only modest activity against SMARCA4 (DC50 > 1000 nM, Dmax = 46%). SMD- 6346 potently and effectively inhibits cell growth in SMARCA4-deficient cancer cell lines and displays minimal cell growth inhibition activity in SMARCA2/4 wild-type cancer cell lines. SMD-6346 attains an excellent pharmacokinetic profile and 61% oral bioavailability in mice. Daily oral administration of SMD-6346 induces robust SMARCA2 depletion in tumor tissues in mice and significantly inhibits tumor growth in the H838 SMARCA4-deficient xenograft model in mice. SMD-6346 is a promising, orally bioavailable  \nSMARCA2 degrader for further optimization for the development of a new therapy for SMARCA4-deficient human cancers.  \n■ INTRODUCTION  \nIn mammals, the multisubunit switch/sucrose nonfermentable (SWI/SNF) complex plays a key role in facilitating chromatin remodeling, thereby in regulating transcriptional regulation and DNA replication. 1−4 The catalytic function of this complex is provided by two mutually exclusive ATP-dependent helicases/ ATPases, namely SMARCA2 (also known as BRM) and its closely related, highly homologous paralogue SMARCA4 (also known as BRG1).5,6 It was discovered that approximate 11% of human cancers including nonsmall-cell lung cancer, ovarian cancer, and melanoma harbor an inactivated, mutated SMARCA4 .7−15 Importantly, SMARCA4-inactivated cancer cells become critically dependent on SMARCA2 for their proliferation and survival, 16−18 establishing SMARCA2 as a synthetic lethal target in SMARCA4-deficient human cancers. Therefore, selectively targeting SMARCA2 has been pursued asa promising therapeutic strategy for the treatment of SMARCA4-deficient human cancers. Because both SMARCA2 and SMARCA4 are functional in normal cells, selective targeting SMARCA2 is expected to have a minimal toxicity on normal cells or normal tissues.17, 18  \nExtensive efforts have been made in the development of smallmolecule inhibitors to target the bromodomain (BRD) or the ATPase domain ofSMARCA2 and SMARCA4. 19−24 It has been demonstrated that inhibitors targeting the BRD domain of SMARCA2 and SMARCA4 (BRD inhibitors) have no effect on tumor cell proliferation with either wild-type SMARCA2/4 or  \ndeficient SMARCA4.19,21,25 Although inhibitors targeting the ATPase domain of SMARCA2 and SMARCA4 effectively inhibit cell growth in vitro and tumor growth in vivo, they are toxic to mice.22,24 Because SMARCA2 and SMARCA4 share the highly conserved bromodomain (BRD) and ATPase domain,5,6 development of small-molecule inhibitors to selectively target SMARCA2 or SMARCA4 has proven to be very challenging. Hence, new strategies were needed to successfully and selectively target SMARCA2 for the treatment of SMARCA4-deficient human cancers.  \nIn recent years, targeted protein degradation (TPD) using the Proteolysis Targeting Chimera (PROTAC) technology has been employed as an effective therapeutic strategy for drug discovery and development.26−29 PROTACs are heterobifunctional small-molecules, which recruit an E3","cbCaiecaFaBOZ3CX","https://ap.wps.com/l/cbCaiecaFaBOZ3CX","pdf",3490821,17,"English","# Abstract\n# Introduction","[{\"question\":\"What therapeutic strategy does the article focus on for SMARCA4-deficient cancers?\",\"answer\":\"It focuses on selectively targeting SMARCA2 via degradation, using SMARCA2 PROTAC degraders to exploit the dependency created by SMARCA4 deficiency.\"},{\"question\":\"What are the key potency and selectivity results for SMD-6346?\",\"answer\":\"SMD-6346 achieves DC50 = 3.3 nM and Dmax \\u003e 90% against SMARCA2, while showing only modest activity against SMARCA4 (DC50 \\u003e 1000 nM, Dmax = 46%).\"},{\"question\":\"How does SMD-6346 perform in biological models regarding cell growth and in vivo exposure?\",\"answer\":\"It potently inhibits cell growth in SMARCA4-deficient cancer cell lines with minimal inhibition in SMARCA2/4 wild-type lines, and it shows an excellent pharmacokinetic profile with 61% oral bioavailability in mice.\"}]","Discovery of SMD-6346 - A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers | PDF",1790083503,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbc171898c11c8fd1fa664462cbfd544.webp",983,1296,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cb0551d4dda13c7125ce9c05de24b82.webp",982,1295,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83ad03f9289d1b50f27931407a6c128d.webp",981,1293,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a6835afad7bb367ab5373c93342ea55.webp",980,1292]